William J. Greenlee
Merck & Co.
331 Papers
5.6K Citations
William J. Greenlee is an academic researcher from Merck & Co.. The author has contributed to research in topics: Angiotensin II & Chemistry. The author has an hindex of 52, co-authored 326 publications. Previous affiliations of William J. Greenlee include Schering-Plough & United States Military Academy.
Chat about Author
Papers
Renin inhibitors containing C-termini derived from mercaptoheterocycles
Wallace T. Ashton,Christine L. Cantone,Laura C. Meurer,Richard L. Tolman,William J. Greenlee,Arthur A. Patchett,R. J. Lynch,Terry W. Schorn,John F. Strouse,Peter K. S. Siegl +9 more
TL;DR: A series of transition-state analogues having heterocyclythio C-termini has been synthesized and evaluated for inhibition of human renin and were moderately potent inhibitors of human plasma renin, having IC50 values of 30-40 nM.
33
The Discovery of Pyridone and Pyridazone Heterocycles as γ-Secretase Modulators
Xianhai Huang,Robert G. Aslanian,Wei Zhou,Xiaohong Zhu,Jun Qin,William J. Greenlee,Zhaoning Zhu,Lili Zhang,Lynn A. Hyde,Inhou Chu,Mary Cohen-Williams,Anandan Palani +11 more
TL;DR: A series of novel pyridazone and pyrIDone compounds as γ-secretase modulators were discovered and displayed very good in vitro activity and excellent selectivity with good in vivo efficacy in both CRND8 mouse and nontransgenic rat models.
33
Imidazo[4,5-b]pyridine-based AT1 / AT2 angiotensin II receptor antagonists
Nathan B. Mantlo,Dooseop Kim,Debra Ondeyka,Raymond S.L. Chang,Raymond S.L. Chang,Salah D. Kivlighn,Salah D. Kivlighn,Peter K. S. Siegl,Peter K. S. Siegl,William J. Greenlee +9 more
TL;DR: The structure-activity relationships of 6-amido-imidazol-based angiostensin II antagonists demonstrate that high affinity for the AT1 and AT2 receptors is largely dependent upon the R1 and R4 substituents.
32
Patent
Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
Yan Xia,Boyle Craig D,William J. Greenlee,Samuel Chackalamannil,Charles Lee Jayne,Andrew Stamford,Xing Dai,Joel M. Harris,Neustadt Bernard R,Santhosh Neelamkavil,Shah Unmesh G,Claire M. Lankin,Hong Liu +12 more
- 20 Oct 2008
TL;DR: In this article, a Bicyclic Heterocycle derivative for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR119 in a patient.
32
Discovery of γ-secretase inhibitors efficacious in a transgenic animal model of Alzheimer’s disease
Theodros Asberom,Zhiqiang Zhao,Thomas A. Bara,John W. Clader,William J. Greenlee,Lynn A. Hyde,Hubert B. Josien,Wei Li,Andrew T. McPhail,Amin A. Nomeir,Eric M. Parker,Murali Rajagopalan,Lixin Song,Gwendolyn T. Wong,Lili Zhang,Qi Zhang,Dmitri A. Pissarnitski +16 more
TL;DR: Attachment of the cyclopropylcarbamate group to the piperidine core of gamma-secretase inhibitors leads to a dramatic increase of their in vitro potency.
31